Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts
Miguel Vizoso(Institut d'Investigació Biomédica de Bellvitge), Jordi Alcaraz(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Manel Esteller(Institució Catalana de Recerca i Estudis Avançats), Marta Gabasa(Institut d'Investigació Biomédica de Bellvitge), Xavier Trepat(Institute for Bioengineering of Catalonia), María Maqueda(Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine), Sebastián Morán(Institut d'Investigació Biomédica de Bellvitge), Luis G. Rigat-Brugarolas(Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine), Antonio Gómez(Universitat de Vic - Universitat Central de Catalunya), Roberto Lugo(Hospital Regional de Alta Especialidad del Bajío), Adriana Velásquez(Institute for Bioengineering of Catalonia), Noemı́ Reguart(Hospital Clínic de Barcelona), Enrique Vidal(Leitat Technological Center), F. Javier Carmona(Institut d'Investigació Biomédica de Bellvitge), José Ramírez(Universidad Nacional de Colombia), Marta Puig(Hospital Clínic de Barcelona), Anna Labernadie(Cell and Tissue Systems (United States))
Cited by 110
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
The role of histone deacetylases (HDACs) in human cancer
|Molecular Oncology|2007|984